Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06952556 · ClinicalTrials.gov registry record · Phase 4

Adductor Canal Block and IPACK Block vs. Isolated Adductor Canal Block for Post-Operative Analgesia Following HTO/DFO/TTO

A Phase 4 study of Analgesia, sponsored by NYU Langone Health.

Recruiting
Registry status
Phase 4
Development phase
100
Enrollment target
1
Study location

NCT06952556 is a Phase 4 study of Analgesia that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 100 participants, above the 88-participant average among 19 other Analgesia trials with a reported enrollment target (14% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06952556, a Phase 4 study of Analgesia, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
Phase 4
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

A randomized, single-blind, single-center study measuring the effects of adductor canal block combined with IPACK infiltration compared to adductor canal block alone on post-operative pain and opioid consumption in patients undergoing high tibial osteotomy (HTO)/distal femoral osteotomy (DFO)/tibial tubercle osteotomy (TTO).

Conditions Studied

Interventions

  • DRUG ACB
  • DRUG IPACK block

Study Locations (1)

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-04-28
Est. Completion 2027-06-28
Phase Phase 4

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT06952556

The ClinicalTrials.gov registry entry for NCT06952556 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 88-participant average among 19 other Analgesia trials with a reported enrollment target (14% higher). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Analgesia appearing as the primary indexed condition, and to 2 interventions - of which ACB is the first listed.

NCT06952556 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06952556 about?

NCT06952556 is a clinical study titled "Adductor Canal Block and IPACK Block vs. Isolated Adductor Canal Block for Post-Operative Analgesia Following HTO/DFO/TTO". A randomized, single-blind, single-center study measuring the effects of adductor canal block combined with IPACK infiltration compared to adductor canal block alone on post-operative pain and opioid consumption in patients undergoing high tibial osteotomy (HTO)/distal femoral osteotomy (DFO)/tibial...

What is the current status of trial NCT06952556?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2025-04-28. Estimated completion is 2027-06-28.

What conditions does trial NCT06952556 study?

This clinical trial studies the following conditions: Analgesia.

What interventions are being tested in trial NCT06952556?

The interventions under investigation include: ACB (DRUG), IPACK block (DRUG).

Who is sponsoring clinical trial NCT06952556?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06952556 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Analgesia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.